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Depression pathogenesis and treatment: what
can we learn from blood mRNA expression?
Nilay Hepgul, Annamaria Cattaneo, Patricia A Zunszain and Carmine M Pariante*
Abstract
Alterations in several biological systems, including the
neuroendocrine and immune systems, have been
consistently demonstrated in patients with major
depressive disorder. These alterations have been
predominantly studied using easily accessible systems
such as blood and saliva. In recent years there has been
an increasing body of evidence supporting the use of
peripheral blood gene expression to investigate the
pathogenesis of depression, and to identify relevant
biomarkers. In this paper we review the current
literature on gene expression alterations in depression,
focusing in particular on three important and interlinked
biological domains: inflammation, glucocorticoid
receptor functionality and neuroplasticity. We also
briefly review the few existing transcriptomics studies.
Our review summarizes data showing that patients with
major depressive disorder exhibit an altered pattern of
expression in several genes belonging to these three
biological domains when compared with healthy
controls. In particular, we show evidence for a pattern of
‘state-related’ gene expression changes that are
normalized either by remission or by antidepressant
treatment. Taken together, these findings highlight the
use of peripheral blood gene expression as a clinically
relevant biomarker approach.
Keywords: depression, gene expression, glucocorti-
coid receptor, inflammation, microarray, mRNA, neuro-
plasticity, peripheral blood, transcriptomics
Introduction
Major depressive disorder (MDD) is a complex disorder
characterized by the interaction between biological,
genetic and environmental factors, and by a pathogenesis
involving alterations in several biological systems. A large
amount of research has been focused on understanding
the underlying mechanisms of MDD, and there is already
a wealth of evidence demonstrating changes not only in
the central nervous system (CNS) but also in the periph-
ery. For example, blood and saliva are useful and accessi-
ble systems that, via relatively low-invasive procedures,
can be used to analyze several biomarkers, such as pro-
teins or metabolites, using quantitative techniques. Using
this approach, hormonal and immunological abnormal-
ities, such as elevated levels of pro-inflammatory cytokines
[1,2], alterations of the hypothalamic-pituitary-adrenal
(HPA) axis [3], changes in neuroplasticity [4], and changes
in oxidative and nitrosative stress pathways [5], have all
been documented in patients with MDD, and are indica-
tive of the ‘neuroprogressive’ nature of MDD [6].
An emerging and useful method to investigate the
pathogenesis of this disorder is the use of peripheral
blood to measure the expression levels of genes. This is a
useful approach in biomarker identification, with oppor-
tunities for both hypothesis-driven biomarker search and
for hypothesis-free transcriptomics-based discovery [7].
‘Blood gene expression’ usually refers to intracellular
RNA from blood, and it is technically associated, in most
cases, with two approaches: the use of tubes for blood
collection that stabilize mRNA from all cells in the blood;
and the extraction of mRNA from separate distinct blood
cell populations. What is really of importance for
researchers is whether blood mRNA can be used as a
proxy for mRNA expression in other tissues that are
more relevant to the pathogenic processes of interest - in
psychiatry and neuroscience, the brain. In this regard,
peripheral blood gene expression is very promising, as
several studies have shown that blood cells share more
than 80% of the transcriptome with other body tissues,
including the brain [8]. For example, Sullivan and collea-
gues compared the transcriptional profiling of 79 human
tissues, including that of whole blood and of several brain
areas. They showed that whole blood shares significant
gene expression similarities with multiple brain tissues,
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in particular for genes encoding for neurotransmitter
receptors and transporters, stress mediators, cytokines,
hormones, and growth factors, all of which are relevant
to MDD [9]. As such, investigating peripheral blood gene
expression appears to be a useful tool for assessing and
understanding MDD.
It is important to mention that biomarker researchers
have previously used the term leukocyte gene expression
to refer to blood gene expression, implying that the
mRNA isolated from blood comes predominantly from
leukocytes (white blood cells) - that is, the cells of the
immune system. This assumption has been largely based
on the notion that erythrocytes, or red blood cells, even
if much more abundant than leukocytes (by a factor of
approximately 1,000), do not have a nucleus and as such
should not have mRNA synthesis. However, most recent
research has suggested that, in fact, whole blood mRNA
comes predominantly from erythrocytes [7].
As mentioned above, there is clear evidence that bio-
logical systems such as the HPA axis and the inflamma-
tory response are altered and can contribute to the
pathogenesis of depression [10,11]. The dysfunction of
these systems is largely thought to be a result of the
activation of stress-related mechanisms, as MDD is
often preceded by acute or chronic stressful experiences
[12]. We and others have proposed an explanatory
model centered on the glucocorticoid receptor (GR),
one of the most important receptors and transcription
factors governing the stress response [3]. Stress can
induce glucocorticoid resistance, that is, a reduction of
GR function, which in turn leads to both HPA axis
hyperactivity and increased inflammation. As communi-
cation occurs between the CNS and the endocrine and
immune systems, an activation of one can affect the
processes of another, and vice versa [13]. Based on this,
we review the current literature on blood gene expres-
sion alterations in MDD. Additionally, we look at bipo-
lar disorder (BPD) studies that consider euthymic or
depressed states, but excluding those that look at manic
states. We focus in particular on three important and
interlinked domains: inflammation, GR functionality and
neuroplasticity. We also briefly review the few existing
transcriptomics studies.
Alterations in the expression of genes involved in
inflammation
The inflammatory theory of MDD emphasizes the role
of psychoneuroimmunological dysfunctions where there
is an activation of the immune system [14-17]. More-
over, MDD is very common in the medically ill, particu-
larly in conditions with an inflammatory component,
such as cardiovascular disease and rheumatoid arthritis,
as well as in autoimmune and neurodegenerative disor-
ders [18,19]. Indeed, patients with MDD have been
consistently shown to have altered levels of pro- and
anti- inflammatory cytokines in circulation [1,2,20], and
postmortem studies have also described gene expression
alterations in a variety of these cytokines [21]. However,
studies on postmortem brains have several limitations
that can affect the results, including the brain region
analyzed, the cause of death and the effect of the antide-
pressant treatments on gene expression. As such,
researchers are using peripheral tissues, such as leuko-
cytes, that have several advantages, which we have
already mentioned [9]. A few studies have assessed the
mRNA levels of genes involved in inflammation in the
peripheral blood of patients with MDD (see Table 1).
For example, Tsao and colleagues found that the expres-
sion of IL-1b, IL-6, TNF-a and IFN-g genes was signifi-
cantly higher in the peripheral blood mononuclear cells
of patients with MDD compared with healthy controls
[22]. Moreover, in a sub-sample of patients, they
demonstrated that IFN-g expression was reduced,
though not normalized, after 3 months of fluoxetine
treatment, suggesting that antidepressants may have
anti-inflammatory properties. Similarly, we have recently
shown altered gene expression levels in a number of
cytokines in the whole blood of patients with MDD
when compared with controls [23]. We have found
higher mRNA levels of IL-1b, IL-6, TNF-a and macro-
phage inhibiting factor (MIF) as well as lower levels of
IL-4. Moreover, we have also found that IL-b, TNF-a
and MIF mRNA levels are predictors of antidepressant
treatment response, as all three show higher baseline
expression in non-responders. Finally, we also demon-
strated that IL-6 expression is reduced after 8 weeks of
antidepressant treatment (escitalopram or nortriptyline)
in responders only, suggesting a unique ability of these
biomarkers to both predict and track the therapeutic
antidepressant response.
The activation of the immune system observed in
patients with MDD is of course not limited to changes in
cytokines production. For example, apolipoprotein E
(ApoE) is a protein produced by macrophages known to
act as an immunomodulator. ApoE is thought to interact
with many immunological processes including suppression
of T cell proliferation, macrophage function regulation
and activation of natural killer T cells [24]. One study
investigated the expression levels of the ApoE receptor,
ApoER2, in lymphocytes of patients with MDD and
healthy controls [25], demonstrating that patients with
MDD had a significantly lower expression of ApoER2
compared with controls. These receptors bind to reelin, an
extracellular matrix glycoprotein that plays crucial roles in
brain development as well as in synaptic plasticity in the
adult brain [26]. Interestingly, blood levels of an isoform
of reelin have also been shown to be reduced in patients
with MDD [27].
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Table 1 Studies examining alterations in the expression of genes involved in inflammation
Citation Type of study Sample Gene Clinical assessments Main findings
Tsao et al.
2006 [22]
Case-control
and follow-up
20
MDD
22
Controls
5-HTT
IL-1b
IL-6
TNF-a
IFN-a
Diagnosis based on DSM-
IV criteria
HDRS
Higher expression of 5-HTT, IL-1b, IL-6, TNF-a and IFN-a in patients with MDD compared with controls. Significant
decreased in expression of 5-HTT and IFN-a after 3 months of fluoxetine treatment.
Cattaneo et
al. 2012 [23]
Case-control
and follow-up
74
MDD
34
Controls
IL-1a
IL-1b
IL-4
IL-6
IL-7
IL-8
IL-10
MIF
TNF-a
Diagnosis based on DSM-
IV or ICD-10 criteria
SCAN
Higher expression of IL-1b, IL-6, MIF and TNF-a and lower expression of IL-4 in patients with MDD compared with
controls.
IL-b, TNF-a and MIF expression predicted antidepressant response.
Significant decrease in IL-6 expression after 8 weeks of antidepressant treatment (escitalopram or nortriptyline) in
responders only.
Suzuki et al.
2010 [25]
Case-control 43
MDD
43
Controls
ApoER2
VLDLR
Diagnosis based on DSM-
IV criteria
HAM-D
BPRS
Lower expression of ApoER2 in patients with MDD compared with controls.
No significant difference in expression of VLDLR.
Galecki et al.
2012 [29]
Case-control 181
rDD
149
Controls
COX-2
MPO
NOS2A
PLA2G2A
Diagnosis based on DSM-
IV criteria
or ICD-10 criteria
CIDI
Higher expression of COX-2, MPO,
NOS2A and PLA2G2A in patients with rDD compared with controls.
Weigelt et al.
2011 [33]
Case-control 24
MDD
22 BPD
45
Controls
TREM-1
DAP12
PU.1
ATF3
EGR3
MXD1
MAFF
NAB2
Diagnosis based on DSM-
IV criteria
SCID-I
Higher expression of TREM-1 and NAB2 in patients with BPD only.
Higher expression of PU.1 in patients with MDD and a trend for higher expression of TREM-1.
Higher expression of ATF3, EGR3, MAFF and MXD1 in patients with both MDD and BPD.
No significant difference in expression of DAP12 in either patient group.
BDI: Beck Depression Inventory; BPD: bipolar disorder; BPRS: Brief Psychiatric Rating Scale; CIDI: Composite International Diagnostic Interview; DSM-IV: Diagnostic and Statistical Manual, Fourth Edition; HAM-D:
Hamilton Rating Scale for Depression; HDRS: Hamilton Depression Rating Scale; ICD-10: International Classification of Diseases - 10th revision; MDD: major depressive disorder; rDD: recurrent depressive disorder; SCAN:
Schedules for Clinical Assessment in Neuropsychiatry, SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorder..
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There is also gene expression evidence for the involve-
ment of key inflammatory enzymes, including cyclooxy-
genase-2 (COX-2), myeloperoxidase (MPO) and inducible
nitric oxide synthase, in the development of MDD [28-30].
These enzymes have been shown to be expressed not only
in immune cells but also in the CNS. Moreover, increased
oxidative and nitrosative stress as sequels of inflammation
have been previously demonstrated postmortem as well as
in animal studies [5,31]. Indeed, a gene expression study
showed higher mRNA levels of COX-2, MPO, inducible
nitric oxide synthase-2A and phospholipase A2
(PLA2G2A) in patients with MDD compared with healthy
controls [32]. Furthermore, an increase in either reductive
or oxidative stress is thought to be involved in the altera-
tion of the expression of several neurotrophic factors, and
will be reviewed below (see neuroplasticity).
Finally, a recent study in patients with MDD and euthy-
mic BPD disorder investigated three key genes involved in
inflammatory processes: triggering receptor expressed on
myeloid cells 1 (TREM-1), DNAX-activation protein of 12
kDa (DAP12), and purine-rich Box-1 (PU.1) [33]. In this
study, peripheral blood mononuclear cells were isolated
from whole blood and gene expression carried out using
purified monocytes. The results showed a significantly
higher expression of PU.1 in patients with MDD and a sig-
nificantly higher expression of TREM-1 in patients with
BPD, with a trend for higher expression in patients with
MDD compared with healthy controls, supporting, again,
the role of inflammation in these disorders.
Alterations in the expression of genes involved in
glucocorticoid receptor functionality
Alterations of the HPA axis, including impairments in glu-
cocorticoid-mediated negative feedback, is a well-estab-
lished and consistent finding in MDD [34]. The GR is
involved in this negative feedback and several studies have
assessed GR expression and functionality in patients with
MDD. These studies have primarily been conducted in
peripheral cell types including immune cells (mononuclear
and polymorphonuclear leukocytes) and fibroblasts (gingi-
val and skin) [34]. Four studies have analyzed mRNA
expression of GR or of GR-related molecules in peripheral
blood (see Table 2). Katz et al. [35] investigated gene
expression of chaperones and co-chaperones of the GR,
such as FK506 binding protein (FKBP)-4 and FKBP-5,
which influence GR function, and of GR target genes
Table 2 Studies examining alterations in the expression of genes involved in GR functionality
Citation Type of
study
Sample Gene Clinical
assessments
Main findings
Katz et al.
2012 [35]
Repeated
measures
106 pregnant women
with history of
depression
BAG1
CDC37L1
FKBP4
FKBP5
NCOR1
NCOA1
NR3C1
HSP70
ST13
STIP1
HSP90
P23
PPP5C
PPIA
PPID
Diagnosis based on
DSM-IV criteria
SCID-I
BDI
Higher expression of BAG1, FKBP5, NCOA1 and PPID during
pregnancy was diminished in patients in a current depressive
state.
Cattaneo et
al. 2012
[23]
Case-
control and
follow-up
74 MDD
34 Controls
FKBP-4
FKBP-5
GR
Diagnosis based on
DSM-IV or ICD-10
criteria
SCAN
Higher expression of FKBP-5 and lower expression of GR in
Patients with MDD compared with controls.
Significant decrease in FKBP-5 expression and increase in GR
expression after 8 weeks of antidepressant treatment
(escitalopram or nortriptyline) in responders only.
Matsubara
et al. 2006
[36]
Case-
control
56 MDD
48 BPD
31 Controls
GRa
GRb
Diagnosis based on
DSM-IV criteria
HDRS
Lower expression of GRa in patients with MDD in a current
depressive state and in remission compared with controls.
Lower expression of GRa in patients with BPD in a current
depressive state and in remission compared with controls.
No significant differences in the expression of GRb.
Fujimoto et
al. 2008
[37]
Case-
control
60 MDD
46 BPD
28 Controls
Glo1 Diagnosis based on
DSM-IV criteria
HDRS
Lower expression of Glo1 in patients with MDD and BPD in a
current depressive state compared with controls.
No significant difference in expression of Glo1 in patients with
MDD and BPD in a remissive state compared with controls.
Expression of Glo1 correlated negatively with depression scores.
BDI: Beck Depression Inventory; BPD: bipolar disorder; DSM-IV: Diagnostic and Statistical Manual, Fourth Edition; HAM-D: Hamilton Rating Scale for Depression;
HDRS: Hamilton Depression Rating Scale; ICD-10: International Classification of Diseases - 10th revision; SCAN: Schedules for Clinical Assessment in
Neuropsychiatry; SCID-I: Structured Clinical Interview for DSM-IV Axis I Disorder.
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during pregnancy in individuals with a history of depres-
sion. They found an upregulation of eight genes during
pregnancy in all patients; however, the expression of BAG
family molecular chaperone regulator 1 (BAG1), FKBP-5,
peptidylprolyl isomerase D (PPID) and nuclear receptor
coactivator 1 (NCOA1) was reduced in mothers who were
in a current depressive state. This suggests that maternal
depression diminishes the pregnancy-related upregulation
of these particular GR-related genes [35]. A part of these
findings was replicated in our recent study, where we also
assessed the expression of FKBP-4, FKBP-5 and GR in
patients with MDD and controls [23]. We found higher
mRNA levels of FKBP-5 and lower levels of GR in patients
with MDD compared with controls. Furthermore, we
found that antidepressant treatment significantly reduces
FKBP-5 levels after 8 weeks in patients who responded to
treatment, and increases GR levels in all patients, suggest-
ing that a successful antidepressant treatment requires a
normalization of GR function.
In a third study, Matsubara et al. [36] investigated two
isoforms of GR in both patients with MDD and with
BPD: GRa, which is able to directly exert glucocorticoid
effects, and GRb, which binds poorly to glucocorticoids
and, by forming heterodimers with GRa, impairs ligand
binding of this isoform and acts as a dominant negative
regulator of GR function [36]. The authors found that
GRa expression was lower in patients with MDD and
with BPD, in both current depressive states and in
remission, compared with healthy controls. This sug-
gests that GRa mRNA reduction is not state-dependent
but a trait-dependent finding in mood disorders. These
findings may seem at odds with the aforementioned
study showing that antidepressant treatment increases
GR expression [23]; however, it is important to note
that most of the patients with depression in the study
by Matsubara et al., even those defined as ‘currently
depressed’, were already on antidepressants at the time
of the gene expression analysis. They found no signifi-
cant differences in the expression of GRb in either
patient groups compared with controls. Lastly, a study
conducted by the same group, again in both patients
with MDD and with BPD, investigated glyoxalase-1
(Glo1) [37], an antioxidant enzyme involved in oxidative
stress and also a GR target gene as it contains consensus
sequences for GR response elements [38]. It has been
suggested that a GR dysfunction may also have an effect
on Glo1 expression and, indeed, the authors found a
lower expression of Glo1 in patients with MDD and
BPD in a current depressive state compared with con-
trols. On the contrary, there was no significant differ-
ence in Glo1 expression in patients with MDD or BPD
in remission when compared with controls. This sup-
ports the notion that a reduced GR function, and thus a
reduced expression of GR target genes like Glo1, is
involved in the pathogenesis of depression, and that
antidepressant treatment is able to restore this dysfunc-
tion. These data are also consistent with our experimen-
tal work showing that antidepressant treatment
increases GR function both in vivo [39-42] and in vitro
[43,44].
Alterations in the expression of genes involved in
neuroplasticity
MDD may also involve an inability of neuronal systems,
especially under stress conditions, to show adaptive plasti-
city, a mechanism known as neuronal plasticity [4] (see
Table 3). Molecular correlations underlying the mechan-
isms of the stress response involve the regulation of sev-
eral neurotrophic factors, one of them being brain-derived
neurotrophic factor (BDNF). To this regard, several studies
have demonstrated reduced serum and plasma BDNF
levels in patients with MDD when compared with con-
trols, and now a few studies have investigated BDNF at
gene expression level. Pandey et al. [45] investigated
BDNF gene expression in both adult and pediatric patients
with MDD and found significantly lower mRNA expres-
sion as well as lower protein levels in both MDD groups
compared with controls [45]. These findings are supported
by another of our studies, where we have also shown sig-
nificantly lower BDNF expression in the peripheral leuko-
cytes of patients with MDD compared with controls [46].
Additionally, we have found a significant increase in
BDNF expression after treatment with the antidepressant
escitalopram as well as a parallel improvement in depres-
sive symptoms. In a similar study, we investigated the
expression of the neuropeptide VGF (non-acronymic) in
the peripheral leukocytes of patients with MDD and con-
trols. VGF is known to be involved in synaptic plasticity
and to be induced by BDNF [47], and we have shown that
VGF expression is significantly lower in patients with
MDD compared with controls [48]. Interestingly, we also
found that expression of VGF is increased after 12 weeks
of escitalopram treatment in those patients whose depres-
sive symptoms were ameliorated. We have recently repli-
cated these data in the aforementioned larger study [23],
where again we show that patients with MDD have lower
mRNA levels of BDNF and VGF, and that antidepressant
treatment (escitalopram or nortriptyline) increases both
BDNF and VGF expression in treatment responders.
In a study of patients with MDD and BPD, Otsuki et al.
did not find any significant differences in BDNF expres-
sion between patients and controls [49]. However, most
of the patients were on antidepressant medication, so this
may explain the lack of differences. Moreover, Otsuki
and colleagues showed state-dependent differences in a
number of other neurotrophic factors, including glial cell
line-derived neurotrophic factor (GDNF), artemin
(ARTN) and neurotrophin-3 (NT-3). These factors have
Hepgul et al. BMC Medicine 2013, 11:28
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Table 3 Studies examining alterations in the expression of genes involved in neuroplasticity
Citation Type of
study
Sample Gene Clinical assessments Main findings
Pandey et al. 2010
[45]
Case-control 25 adult
MDD
25 adult
controls
14 pediatric
MDD
14 pediatric
controls
BDNF Diagnosis based on DSM-IV
criteria
HDRS
CARS-M
CDRS
YMRS
Lower expression of BDNF in both adult and pediatric patients with MDD compared with controls.
Lower protein levels of BDNF in both adult and pediatric patients with MDD compared with controls.
Cattaneo et al.
2010a [46]
Case-control
and follow up
21 MDD
23 Controls
BDNF Diagnosis based on DSM-IV
or ICD-10 criteria
MADRS
Lower expression of BDNF in patients with MDD compared with controls.
Significant increase in expression of BDNF after escitalopram treatment as well as symptom
improvement.
Cattaneo et al.
2010b [48]
Case-control
and follow up
25 MDD
25 Controls
VGF Diagnosis based on DSM-IV
or ICD-10 criteria
MADRS
Lower expression of VGF in patients with MDD compared with controls.
Significant increase in expression of VGF after 12 weeks of escitalopram treatment in responders only.
Cattaneo et al.
2012 [23]
Case-control
and follow up
74 MDD
34 Controls
BDNF
VGF
Diagnosis based on DSM-IV
or ICD-10 criteria
SCAN
Lower expression of BDNF and VGF in patients with MDD compared with controls.
Significant increase in BDNF and VGF expression after 8 weeks of antidepressant treatment (escitalopram
or nortriptyline) in responders only.
Otsuki et al. 2008
[49]
Case-control 60 MDD
42 BPD
28 Controls
BDNF
NGF
NT-3
NT-4
GDNF
ARTN
NRTN
PSPN
Diagnosis based on DSM-IV
criteria
HDRS
Lower expression of GDNF, ARTN and NT-3 in patients with MDD in a current depressive state compared
with those in remission and controls.
No significant difference in expression of GDNF, ARTN or NT-3 in patients with BPD.
No significant difference in expression levels of BDNF, NGF or NT-3 among the three groups.
Su et al. 2009 [54] Case-control 16 MDD
14 Controls
p11 Diagnosis based on DSM-IV
criteria
MINI
HAM-D
HARS
Higher expression of p11 in patients with MDD compared with controls.
Zhang et al. 2011
[55]
Case-control 38 BPD
14 Controls
p11 Diagnosis based on DSM-IV
criteria
MINI
HDRS-17
YMRS
Higher expression of p11 in patients with BPD compared with controls.
Iga et al. 2007 [57] Case-control 42 MDD
32 Controls
VEGF Diagnosis based on DSM-IV
criteria
SIGH-D 17
Higher expression of VEGF in patients with MDD compared to controls.
Dome et al. 2009
[58]
Case-control 33 MDD
16 Controls
CD34
CD133
VEGFR2
Diagnosis based on DSM-IV
criteria
BDI
Lower expression of VEGFR2 and CD133 in patients with MDD compared with controls.
Expression of VEGFR2 and CD133 correlated negatively with BDI scores.
Anitha et al. 2008
[59]
Case-control 33 MDD
21 BPD
57 Controls
PCNT2 Diagnosis based on DSM-IV
criteria
BPRS
HAM-D
Higher expression of PCNT2 in patients with MDD compared with controls.
Higher expression of PCNT2 in patients with BPD in a remission state compared with controls.
Nakataki et al.
2011 [60]
Case-control 27 MDD
27 Controls
EMP1 Diagnosis based on DSM-IV
criteria
HAM-D
Lower expression of EMP1 in patients with MDD compared with controls.
A trend increase in expression of EMP1 after 8 weeks of antidepressant treatment
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Table 3 Studies examining alterations in the expression of genes involved in neuroplasticity (Continued)
Wakabayashi et al.
2008 [64]
Case-control 60 MDD
42 BPD
28 Controls
NCAM-
140
L1
VCAM-1
ICAM-1
E-
cadherin
Diagnosis based on DSM-IV
criteria
HDRS
Lower expression of NCAM-140 in patients with BPD in a current depressive state, but not in a remissive
state, compared with controls and patients with MDD.
Higher expression of L1 in patients with BPD in a current depressive state, but not in a remissive state,
compared with controls and patients with MDD.
No significant differences in expression of NCAM-140 or L1 in patients with MDD compared with
controls.
No significant differences in expression of ICAM-1, VCAM-1 or E-cadherin in patients with MDD or BPD in
a current depressive state compared to controls.
Otsuki et al. 2010
[68]
Case-control 60 MDD
46 BPD
28 Controls
REST
CRH
5-HT1A
Adcy5
CaMKIIa
Epor
IGF1R
Tnfsf10
Tnfsf11
Tnfsf12-
12
Diagnosis based on DSM-IV
criteria
HDRS
Lower expression of REST in patients with MDD compared with controls.
Higher expression of CRH, Adcy5 and Tnfsf12-13 in patients with MDD in a current depressive state
compared with those in a remissive state.
No significant difference in expression of REST or any other mRNAs in patients with BPD compared with
controls.
BDI: Beck Depression Inventory; BPD: bipolar disorder; CARS-M: Clinician Administered Rating Scale for Mania; CDRS: Children Depression Rating Scale; DSM-IV: Diagnostic and Statistical Manual, Fourth Edition; HAM-
D: Hamilton Rating Scale for Depression; HARS: Hamilton Anxiety Rating Scale; HDRS: Hamilton Depression Rating Scale; ICD-10: International Classification of Diseases - 10th revision; MADRS: Montgomery-Asberg
Depression Rating Scale; MDD: major depressive disorder; MINI: Mini International Neuropsychiatric Interview; SIGH-D-17: Structure Interview Guide for the 17-item Hamilton Depression Rating Scale; YMRS: Young
Mania Rating Scale.
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previously been shown to be associated with stress
response in animal models [50] as well as with depression
and suicide in humans [51]. Specifically, they demon-
strated that patients with MDD in a current depressive
state have lower expression of GDNF, ARTN and NT-3
compared with those in remission as well as controls.
However, they did not find any significant differences in
the expression levels of these three factors in BPD
patients in depressive or remissive states, suggesting that
the changes in the expression of these genes are asso-
ciated with MDD only, and may be state-dependent.
Another protein related to BDNF is p11, a member of
the S-100 family known to be involved in the regulation
of a number of cellular processes such as cell cycle pro-
gression and differentiation [52,53]. Interestingly, two
studies have found p11 to be overexpressed in patients
compared with healthy controls. Su et al. demonstrated
that patients with MDD had a higher expression of p11
compared with controls [54], and Zhang et al. found the
same results in patients with BPD [55]. However, in
both of these studies the patients were medicated. Con-
versely, in our recent study we reported lower mRNA
levels of p11 in drug-naïve patients with MDD com-
pared with controls [23]. Furthermore, after 8 weeks of
antidepressant treatment, p11 levels were significantly
increased. We have also recently demonstrated that p11
mRNA levels are increased by antidepressant treatment
in vitro in a human neuronal hippocampal model [43],
thus showing also the unique ability of a gene expres-
sion approach to be used consistently across different
experimental approaches.
As mentioned earlier, the expression of neurotrophic
factors can be altered particularly in response to oxida-
tive or reductive stress. One such neurotrophic factor is
vascular endothelial growth factor (VEGF). Increased
expression of VEGF has previously been shown in per-
ipheral monocytes of patients with diabetes with coron-
ary artery disease [56]. Given the high prevalence of
depression in patients with coronary artery disease,
VEGF mRNA levels have been proposed as a putative
biological marker for MDD. Indeed, Iga and colleagues
measured VEGF expression in the peripheral leukocytes
of patients with MDD and showed that VEGF expres-
sion was higher in patients with MDD compared with
healthy controls [57]. A similar study by Dome et al.
[58] investigated the expression levels of VEGF recep-
tor-2 (VEGFR2) in the peripheral blood of patients with
MDD. They showed a lower expression of VEGFR2 in
patients with MDD compared with healthy controls.
Moreover, the expression of VEGFR2 negatively corre-
lated with depression scores, thus supporting the role of
VEGF signaling in MDD pathogenesis [58].
Two further molecules regulating neurogenesis have
been found to be altered in depression: pericentrin 2
(PCNT2) and epithelial membrane protein 1 (EMP1).
PCNT2 is a disrupted in schizophrenia 1-interacting
protein that regulates cell proliferation, differentiation
and migration, and outgrowth of neuronal axons and
dendrites. In a study of patients with MDD and BPD,
mRNA levels of PCNT2 were found to be significantly
higher in drug-naïve patients with MDD compared with
controls [59]. Interestingly, PCNT2 expression was also
higher in patients with BPD in a remission state when
compared with controls. EMP1 is involved in neurogen-
esis mechanisms as it interacts with transforming
growth factor beta signaling. In drug-naïve patients with
MDD, EMP1 levels were significantly lower when com-
pared with controls and, after 8 weeks of antidepressant
treatment, EMP1 mRNA levels showed a trend towards
an increase [60].
Cell adhesion molecules such as neural cell adhesion
molecule (NCAM) and L1 are also known to play
important roles in synaptic plasticity, and have been
indicated to have altered expression in the cerebrospinal
fluid and brain of patients with a mood disorder
[61-63]. Several studies conducted in peripheral blood
mRNA confirm this. For example, Wakabayashi et al.
[64] assessed the expression of NCAM-140 and L1 in
the leukocytes of patients with MDD and BPD, as well
as controls. They found a lower expression of NCAM-
140 in patients with BPD in a current depressive, but
not in a remissive, state compared with both controls
and patients with MDD [64]. They also found a higher
expression of L1, again in patients with BPD in a
depressive state but not in those in remission compared
with controls and patients with MDD. Interestingly, they
did not find any significant differences in the expression
of these molecules in patients with MDD when com-
pared with controls. This suggests that the alterations in
the expression of both NCAM-140 and L1 are specific
to BPD and are also state dependent. In addition, no
changes were found for intercellular adhesion molecule-
1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1) or E-cadherin expression, in patients with either
MDD or BPD compared with controls.
Repressor element-1 silencing transcription factor
(REST) is a modulator protein that is also known to be
involved in synaptic plasticity [65]. It has been recently
shown that REST is involved in the synthesis of cortisol
[66] and in neurogenesis [67], both of which are of rele-
vance to mood disorders. Otsuki and colleagues investi-
gated the expression of REST and a variety of its target
genes including corticotropin-releasing hormone (CRH),
adenylate cyclise 5 (Adcy5) and TNF superfamily mem-
ber 12-13 (TNFsf12-13) in patients with MDD and BPD
[68]. They found a lower expression of REST in patients
with MDD compared with controls. Furthermore, they
investigated whether altered expression of these mRNAs
Hepgul et al. BMC Medicine 2013, 11:28
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were state or trait dependent, reporting a higher expres-
sion of CRH, Adcy5 and TNFsf12-13 in patients with
MDD in a current depressive state compared with those
in a remissive state. Interestingly, they found no signifi-
cant differences in the expression of REST or any other
mRNAs in patients with BPD when compared with
controls.
Transcriptomics studies
The use of high-throughput technologies like microarray
platforms allows for the exploration of the expression
levels of the entire genome and thus the identification of
gene expression differences by using a hypothesis-free
approach (See Table 4). Beech et al. used microarrays con-
taining >48,000 transcript probes to investigate gene
expression in the peripheral blood of patients with BPD
compared with healthy controls [69]. They found a total of
1,180 differentially expressed genes, 559 of which were
upregulated in patients with BPD and 621 that were
downregulated. Using pathway analysis they were able to
identify functional pathways that were significantly differ-
ent between patients and controls, including pathways
involved in gene transcription, immune response, apopto-
sis and cell survival. In particular, they found differences
in the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-B) signaling pathway, which plays
important roles in transcription regulation and immune
response mechanisms. This is in line with a previous study
showing increased DNA binding of NF-B in peripheral
blood mononuclear cells of patients with MDD in
response to an acute stressor [70]. Another microarray
study focusing on postpartum depression identified 73 dif-
ferentially expressed genes in mothers with postpartum
depression compared with control mothers [71]. Of inter-
est, the authors observed a reduction in the expression of
genes involved in immune modulation, transcriptional
activation, cell cycle and proliferation, as well as DNA
replication and repair processes. As previously mentioned,
neuronal plasticity as well as cell survival are important
processes involved in MDD and even in the effects of anti-
depressant drugs [72]. Indeed, one microarray study inves-
tigated gene expression changes in response to the
serotonin-norepinephrine reuptake inhibitor venlafaxine
in elderly patients with MDD [73]. The authors found 57
out of 8,000 sequences examined to have an altered
expression after 4 weeks of antidepressant treatment. The
genes found to be differentially expressed belong to the
biological systems we have already discussed, including
those involved in cell survival, ionic homeostasis, neural
plasticity, signal transduction and metabolism. Lastly, a
Table 4 Studies using transcriptomics
Citation Type of study Sample GENE
Technique
Clinical
assessment
Main findings
Beech et al.
2010 [69]
Case-control 20 BPD
15 Controls
Microarray Diagnosis based
on DSM-IV criteria
SCID
HDRS
MADRS
HARS
YMRS
Altered expression of 1180 genes in patients with BPD
compared with controls.
Higher expression of 559 genes and lower expression of 621
genes.
Top three functional pathways affected were the
mitochondrial electron transport chain, notch signaling and
NF-b signaling pathways.
Segman et
al. 2010 [71]
Case-control 10 mothers with
postpartum
depression
10 control
mothers
Microarray Diagnosis based
on DSM-IV criteria
SCID
EPDS
Altered expression of 73 genes in mothers with postpartum
depression compared with controls mothers.
Lower expression of 71 genes in mothers with postpartum
depression including genes related to transcriptional
activation, cell cycle and proliferation, nucleotide binding, and
DNA replication and repair.
Kalman et al.
2005 [73]
Repeated
measures
6 elderly MDD Microarray Diagnosis based
on ICD-10 criteria
BDI
HAM-D
GDS
MMSE
Altered expression of 57 genes after 4 weeks of venlafaxine
treatment when compared to baseline expression levels.
Lower expression of 26 and higher expression of 31 including
genes involved in cell survival, ionic homeostasis, neural
plasticity, signal transduction and metabolism
Yi et al.
2012 [74]
Case-control 8 MDD
8 SSD
8 Controls
Microarray Diagnosis based
on DSM-IV criteria
HDRS-17
Altered expression of 149 genes in patients with MDD and
1,456 genes in patients with SDD compared with controls.
Functional pathways affected included IL-2- and IL6-mediated
signaling and TNF receptor signaling in patients with MDD
and cytokine-cytokine receptor interactions and G protein
signaling pathway in patients with SDD.
BDI: Beck Depression Inventory; BPD: bipolar disorder; BPRS: Brief Psychiatric Rating Scale; CIDI: Composite International Diagnostic Interview; DSM-IV: Diagnostic
and Statistical Manual, Fourth Edition; EPDS: Edinburgh Postnatal Depression Scale; GDS: Geriatric Depression Scale; HAM-D: Hamilton Rating Scale for Depression;
HDRS: Hamilton Depression Rating Scale; ICD-10: International Classification of Diseases - 10th revision; MADRS: Montgomery-Asberg Depression Rating Scale;
MDD: major depressive disorder; MMSE: Mini-Mental State Examination; SCAN: Schedules for Clinical Assessment in Neuropsychiatry; SCID-I: Structured Clinical
Interview for DSM-IV Axis I Disorder; SSD: subsyndromal symptomatic depression; YMRS: Young Mania Rating Scale.
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study in 2012 conducted microarray analysis in lympho-
cytes from patients with MDD and subsyndromal sympto-
matic depression (SSD) [74]. In patients with MDD, they
found 149 differentially expressed genes, enriched in 53
pathways, in comparison with control participants. Path-
way analyses identified significant differences for IL-2 and
IL-6-mediated signaling as well as TNF receptor signaling
pathways. In patients with SSD, they identified 1,456 genes
and 47 pathways that were significantly different when
compared with controls, with 20 genes overlapping with
those found in patients with MDD. Pathways found to be
differentially expressed in patients with SSD included cyto-
kine-cytokine receptor interactions and G protein signal-
ing. Only two pathways were found to be involved in both
MDD and SSD: the mitogen-activated protein kinase sig-
naling pathway and the Wnt signaling pathway, both of
which have been previously implicated in mood disorders
[75,76].
Although strictly speaking not a transcriptomics study
in patients with depression, it is worth mentioning our
recent study in the human hippocampal cells model
[77]. In this study, we mimicked depression ‘in a dish’
by incubating cells with stress-level concentrations of
the main human glucocorticoid hormone, cortisol. Tran-
scriptomics analyses have identified inhibition of the
‘Hedgehog pathway’ as a candidate mechanism by which
depression can reduce neurogenesis. It is of interest
that, in the same study, we also found that Hedgehog-
signaling is inhibited in the hippocampus of adult prena-
tally stressed rats with high glucocorticoid levels, again
confirming the ability of gene expression approach to
identify findings that are replicated consistently across
different experimental models.
Conclusions
We have presented data on peripheral mRNA gene
expression in patients with depression across MDD and
BPD, obtained from whole blood, isolated mononuclear
cells and isolated monocytes. All studies identified a pat-
tern of altered expression in several genes belonging to
three biological systems of interest: inflammation, GR
functionality and neuroplasticity. Of note is the frequent
pattern of state-related gene expression changes that are
normalized either by remission or by antidepressant treat-
ment. The association between gene expression and treat-
ment response identifies this biomarker approach as
particularly relevant from a clinical point of view. How-
ever, the temporal relationship of these gene expression
changes with other factors, such as exposure to stress, is
still unclear. This is relevant especially considering the fre-
quent occurrence of stressors in these clinical groups. For
example, a study on socioeconomic circumstances used
transcriptome gene expression measurements followed by
bioinformatics analysis of genes whose expression is
regulated by specific transcription factors, including the
GR and NF-B. The authors described an upregulation of
target genes for NF-B and a downregulation of target
genes for GR, consistent with a pattern of glucocorticoid
resistance and increased inflammation, that is, a pattern
similar to that described in depression [78]. We also do
not know whether some of these changes in gene expres-
sion represent the marker of a genetic predisposition to
encounter psychopathology; for example, we have pre-
viously shown that genetic variants in CNS and immune
genes increase the association between depression and
inflammation [79].
It should also be noted that the many pathways involved
in the onset of depressive symptoms are of course interre-
lated and dynamic in nature. Because of this complexity, it
has been proposed that a systems biology approach, com-
bining information from gene expression analysis, protein
data and well-validated animal models, is necessary to
untangle the exact relevant pathways as well as novel
molecular mechanisms [80]. Despite these unanswered
questions, peripheral blood gene expression is a strong
and clinically relevant system to identify biomarkers
related to pathology and treatment response, and also to
discover unknown mechanisms underlying the develop-
ment of mood disorders. The identification of both could
help in the personalization of therapy and in the future
development of novel treatments.
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